<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>埃森哲（ACN）表示，通过埃森哲风险投资公司已投资于 Iridius，这是一家企业级人工智能基础设施公司，专为高度监管的行业（包括生命科学和制药领域）设计合规的人工智能解决方案。埃森哲和 Iridius 还将建立战略合作伙伴关系，以支持生命科学组织在人工智能应用方面的扩展。投资条款未披露。</p>
<p>埃森哲和 Iridius 将构建覆盖生命科学价值链的端到端合规工作流程，从监管提交和药物警戒到临床和制造操作。</p>
<p>截至最后收盘，埃森哲的股价为 178.28 美元，下跌 6.22%。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

埃森哲

铱星通讯

<p>埃森哲（ACN）通过埃森哲风险投资公司投资了铱星通讯，这是一家企业级人工智能基础设施公司。此次投资旨在增强生命科学和制药等受监管行业的人工智能解决方案。此外，埃森哲和铱星通讯将建立战略合作伙伴关系，以促进生命科学组织中的人工智能应用，重点关注整个价值链的合规工作流程。投资条款未披露，埃森哲的股票交易价格为 178.28 美元，下跌 6.22%</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Accenture (ACN) said it has invested, through Accenture Ventures, in Iridius, an enterprise AI infrastructure company that designs compliant-by-design AI solutions for highly regulated industries, including life sciences and pharmaceuticals sectors. Accenture and Iridius will also form a strategic partnership to support life sciences organizations in scaling AI adoption. Terms of the investment were not disclosed.</p>
<div class="lb-trans"><p>埃森哲（ACN）表示，通过埃森哲风险投资公司已投资于 Iridius，这是一家企业级人工智能基础设施公司，专为高度监管的行业（包括生命科学和制药领域）设计合规的人工智能解决方案。埃森哲和 Iridius 还将建立战略合作伙伴关系，以支持生命科学组织在人工智能应用方面的扩展。投资条款未披露。</p>
</div><p>Accenture and Iridius will build end-to-end compliance workflows across the life sciences value chain, from regulatory submissions and pharmacovigilance to clinical and manufacturing operations.</p>
<div class="lb-trans"><p>埃森哲和 Iridius 将构建覆盖生命科学价值链的端到端合规工作流程，从监管提交和药物警戒到临床和制造操作。</p>
</div><p>At last close, Accenture shares were trading at $178.28, down 6.22%.</p>
<div class="lb-trans"><p>截至最后收盘，埃森哲的股价为 178.28 美元，下跌 6.22%。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

埃森哲宣布投资 Iridius